
    
      OBJECTIVES: I. Determine the toxicity and maximum tolerated dose of 131-iodine-labeled
      monoclonal antibody fragment Me1-14 F(ab')2 administered intrathecally in patients with
      neoplasms metastatic to the leptomeninges. II. Identify objective therapeutic responses to
      this treatment.

      OUTLINE: Radioimmunotherapy. Iodine-131-Labeled Monoclonal Antibody Fragment Me1-14 F(ab')2,
      131I-Me1-14 F(ab')2.

      PROJECTED ACCRUAL: Three to 6 patients will be treated at each dose studied.
    
  